ReviewFrontiers in neuroscience2024
Psilocybin for the treatment of Alzheimer's disease.
Review in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives.Human psychopharmacology · 2026Review
- Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD).Brain sciences · 2026Review
- Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026Review
- From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials.Metabolic brain disease · 2026Review
- Transient multidomain functional improvement in advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration: a case report.Frontiers in neuroscience · 2026Article
- Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?Dialogues in clinical neuroscience · 2025Review
- Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?Medical sciences (Basel, Switzerland) · 2025Review
- Targeting Oligodendrocyte Dysfunction in Alzheimer's Disease: a New Frontier for Drug Repurposing with Antihistamines and Serotonin Receptor Agonists.Journal of molecular neuroscience : MN · 2025Review
- Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.Psychological medicine · 2025Article
- Psilocybin-assisted psychotherapy for Parkinson's disease without depression: A case-report.Journal of Parkinson's disease · 2025Article
- Advances in Psychoactive Alkaloid Delivery, Ergoline Analogues, and Serotonin Receptor Modulation for Enhanced Therapeutic Outcomes.ACS medicinal chemistry letters · 2025Article
- Advancements in Neurotechnology: Pioneering Brain Monitoring and Stimulation for Enhanced Treatment and Understanding.ACS medicinal chemistry letters · 2025Article
- Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.Frontiers in dementia · 2025Review
- Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.Neuropsychiatric disease and treatment · 2025Review
- Advances in Psychedelic Therapeutics: Novel Prodrugs and Derivatives for Enhanced Mental Health Treatment.ACS medicinal chemistry letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) stands as a formidable neurodegenerative ailment and a prominent contributor to dementia. The scarcity of available therapies for AD accentuates the exigency for innovative treatment modalities. Psilocybin, a psychoactive alkaloid intrinsic to hallucinogenic mushrooms, has garnered attention within the neuropsychiatric realm due to its established safety and efficacy in treating depression. Nonetheless, its potential as a therapeutic avenue for AD remains largely uncharted. This comprehensive review endeavors to encapsulate the pharmacological effects of psilocybin while elucidating the existing evidence concerning its potential mechanisms contributing to a positive impact on AD. Specifically, the active metabolite of psilocybin, psilocin, elicits its effects through the modulation of the 5-hydroxytryptamine 2A receptor (5-HT2A receptor). This modulation causes heightened neural plasticity, diminished inflammation, and improvements in cognitive functions such as creativity, cognitive flexibility, and emotional facial recognition. Noteworthy is psilocybin's promising role in mitigating anxiety and depression symptoms in AD patients. Acknowledging the attendant adverse reactions, we proffer strategies aimed at tempering or mitigating its hallucinogenic effects. Moreover, we broach the ethical and legal dimensions inherent in psilocybin's exploration for AD treatment. By traversing these avenues, We propose therapeutic potential of psilocybin in the nuanced management of Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.